Company: CYTK
Filing Date: 2025-03-31
Form Type: PRE 14A
Source: 0001140361-25-011212
Chunk: 54

Company: CYTOKINETICS INC
Filing Date: 2025-03-31
Form: PRE 14A
Chunk 54
---
. Lee served as the Chief Financial Officer of Vir Biotechnology, Inc., an immunology company from March 2023 to May 2024, and from February 2021 to March 2023, he served as Chief Financial Officer and Management Board member of MorphoSys AG, a biopharmaceutical company. Prior to that, from October 2019 to February 2021, he served as the Executive Vice President and Chief Financial Officer of Sangamo Therapeutics, Inc., a biotechnology company. From December 2005 to October 2019, Mr. Lee served in various roles at Gilead Sciences, Inc., a biopharmaceutical company, most recently as Senior Vice President, Financial Planning & Analysis and Investor Relations from March 2019 to October 2019. Previously, Mr. Lee served as Vice President of Financial Planning & Analysis and Investor Relations from September 2018 to February 2019, Vice President of Investor Relations from June 2016 to August 2018 and Senior Director, Investor Relations from 2013 to May 2016. From 2010 to 2013, Mr. Lee was the Head of Europe Financial Planning & Analysis and prior to that served as the Head of Research & Development Financial Planning & Analysis from 2006 to 2010. Mr. Lee received a B.A. from the University of California, Irvine and an M.B.T. from the University of Southern California.

| Cytokinetics, Inc.|2025 Proxy Statement |     | 37 |

TABLE OF CONTENTS

Executive Compensation Compensation Discussion and Analysis This Compensation Discussion and Analysis explains our compensation philosophy, policies and practices for 2024 for the following individuals, who we refer to as our “named executive officers”:

| Name                       |     | Position                                                |
| Robert I. Blum             |     | President and Chief Executive Officer                   |
| Andrew M. Callos           |     | Executive Vice President, Chief Commercial Officer      |
| Sung H. Lee                |     | Executive Vice President, Chief Financial Officer       |
| Fady I. Malik, M.D., Ph.D. |     | Executive Vice President, Research and Development      |
| Brett Pletcher             |     | Former Executive Vice President and Chief Legal Officer |
| Ching W. Jaw               |     | Former Senior Vice President, Chief Financial Officer   |

Mr. Blum is our Principal Executive Officer (“PEO”). Mr. Lee is our Principal Financial Officer (“PFO”). Mr. Jaw has